Niagen Bioscience, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
NAGE Nasdaq 2840 www.niagenbioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Niagen Bioscience, Inc.

Niagen (NAGE) Q3 2026 Earnings Call Transcript - Nov 5th, 2026 8:20 am
Niagen Bioscience Inc (NAGE) Q3 2026 Earnings Call Highlights: Cash Flow Positive Despite Sales ... - Nov 5th, 2026 4:11 am
Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates - Nov 4th, 2026 4:45 pm
Niagen Bioscience: Q3 Earnings Snapshot - Nov 4th, 2026 2:55 pm
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results - Nov 4th, 2026 2:02 pm
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know - Nov 2nd, 2026 7:00 am
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline - Oct 28th, 2026 7:00 am
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion - Oct 22nd, 2026 6:38 am
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product - Oct 20th, 2026 6:32 am
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 - Oct 15th, 2026 6:32 am
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) - Oct 8th, 2026 6:32 am
Niagen Bioscience to Present at LD Micro 20th Annual Main Event - Oct 6th, 2026 6:32 am
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater - Oct 1st, 2026 6:32 am
Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth? - Sep 30th, 2026 10:59 am
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial - Sep 30th, 2026 6:32 am
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes - Sep 21st, 2026 6:32 am
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth - Sep 17th, 2026 6:32 am
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit - Sep 10th, 2026 6:32 am
Niagen Bioscience to Present at Longevity Investors Conference - Sep 2nd, 2026 6:32 am
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit - Aug 26th, 2026 6:32 am